GH TO Igf1 Conversion

Why this article exists

Every peptide reader who runs a GH-axis compound eventually asks a version of the same question:

• “My IGF-1 lab was 186 baseline. I started 2.4 IU of HGH — it went to 265. I raised the dose to 4 IU — the next test came back at 250. Why did more HGH not produce more IGF-1?”
• “Why isn’t my Tesamorelin dose linearly raising my IGF-1?”
• “Why did my friend on the same CJC/Ipa protocol get better results than me?”

The answer is not “your peptide isn’t working” and it is not “raise the dose.” It is that GH is only the upstream signal. The IGF-1 that produces the effects the reader is actually chasing is made downstream by the liver, and that conversion is gated by three signals the reader controls. Dial those signals in and the peptide protocol delivers. Skip them and no amount of dose adjustment will fix it. This article documents that mechanism honestly.

The mechanism — GH → liver → IGF-1

The pathway, in the order it actually runs:

1. Something raises GH. Either a GH-secretagogue peptide binds pituitary receptors and drives a physiologic pulse (CJC-1295 on the GHRH receptor, Ipamorelin on the ghrelin receptor, and their blend on both at once), or an exogenous HGH injection floods circulating GH directly (covered in Somatropin, IGF-1 DES, PEG-MGF — the exogenous GH / IGF reference).
2. GH circulates and binds GH receptors on the liver and on peripheral tissues. On peripheral tissues (fat, connective tissue), GH does direct work — including lipolysis via hormone-sensitive lipase, which is where the “GH before bed, fasted” fat-loss timing comes from.
3. In the liver, GH signal drives IGF-1 production — but the production step requires available substrate + insulin signaling. Insulin is the trigger that flips the liver from “GH is here” into “make IGF-1.” When the reader eats carbs after a fasted GH exposure, the resulting insulin rise is what converts that circulating GH into hepatic IGF-1 output.
4. IGF-1 leaves the liver and does the actual work. Muscle protein synthesis, collagen synthesis, tissue repair, glucose disposal, satellite cell activation. IGF-1 is the mediator most readers are chasing when they say “I want the GH benefits.”

The frame that makes this useful: GH is the coach on the sideline; IGF-1 is the player on the field. More coaching doesn’t score points if the players can’t execute. And in this pathway, whether the players execute is determined by the three signals below.

The three signals that gate GH → IGF-1 conversion

This is the part that matters. Any reader whose IGF-1 labs are not tracking with their GH dose is failing one or more of these three, not failing on peptide selection.

Signal 1 — caloric intake

The liver cannot manufacture IGF-1 out of nothing. It needs amino acids, energy, and the insulin signal that eating provides. Undereat and the conversion stalls regardless of how much GH is circulating. This is why every serious bodybuilder documentary shows guys spending most of the day eating — and it is why practitioners see the same pattern in wellness-tier users: someone runs a GH-secretagogue at 300 mcg daily, undereats because they’re chasing fat loss, and then asks why their IGF-1 didn’t move.

Operational rule: If the goal includes IGF-1-mediated benefits (recovery, muscle preservation, collagen, joint feel), the calorie and protein intake has to be high enough to fuel the conversion. Aggressive fat-loss deficits mute IGF-1 output. Get lean first if that’s the priority, then eat for conversion once composition is where the reader wants it.

Signal 2 — estrogen (E2) within a healthy range

Estrogen modulates the GH-axis, and crashed estrogen crashes IGF-1 output. This shows up most visibly in men who run aromatase inhibitors aggressively — E2 drops out of physiologic range, and the same GH-secretagogue protocol that raised IGF-1 last cycle now produces nothing this cycle. The mechanism is the estrogen signaling that participates in hepatic IGF-1 production; take it too far below range and the liver’s conversion capacity drops with it.

Operational rule for men on gear: target E2 in the 40–60 pg/mL range while running a GH-axis peptide protocol. Crashed E2 = wasted peptide + wasted money. For most wellness-tier users not on gear, this signal takes care of itself — endogenous E2 in the normal range does what it needs to do. It becomes actionable when a user is layering an aromatase inhibitor over a GH-axis protocol without realizing the two work against each other.

Signal 3 — training intensity that produces an adaptation demand

The body does not build a hormone it does not need. GH-driven IGF-1 output responds to demand: a training session that produces a real adaptation signal (“I am not currently strong enough to do what I’m being asked to do”) upregulates the whole recovery axis, including IGF-1. Sessions that don’t push adaptation — the same weights every week, no progressive overload, no honest intensity — don’t produce the demand signal, and IGF-1 output stays flat regardless of GH dose.

The delta the practitioner community keeps noticing: the biggest, strongest users in any gym are not the ones asking every week which supplement to add. They dialed the foundations — eating, training with real intensity, recovery — and the protocol became the small tuning lever on top of that. The users who cycle through peptide after peptide looking for the missing piece are usually missing one of the three signals above, not the peptide.

Operational rule: Foundation-first. If nutrition, training intensity, and sleep are not dialed, adding more peptide (or a stronger peptide) will not fix the IGF-1 output. Fix the foundation, then use the peptide protocol as amplification.

The HGH-timing paradox — lipolysis vs anabolic

Once the three signals are dialed, the timing of a GH exposure determines which downstream effect dominates. This is the same molecule producing two different effects in two different metabolic contexts:

Goal	Protocol	Mechanism
Fat loss primary	GH exposure pre-bed, fasted	Insulin is LOW → GH does lipolysis via hormone-sensitive lipase during sleep hours. Morning meal then converts residual GH to IGF-1 for tissue repair. Mirrors natural GH pulse rhythm.
Anabolic primary	GH exposure post-workout + carbs within 30–60 min	Carb-driven insulin rise triggers hepatic GH → IGF-1 conversion. Anabolic signal amplified.

For most wellness-tier users chasing the recovery / body-composition / joint-feel combination, the pre-bed-fasted protocol is the default because it captures both effects in sequence (nighttime lipolysis + morning-meal conversion to IGF-1). Post-workout dosing shifts the balance to the anabolic side at the cost of the fat-loss window.

A sharper anabolic option than post-workout GH: keep the GH-axis peptide protocol on its pre-bed schedule and layer a very-short-half-life direct IGF-1 signal (IGF-1 DES, intramuscular into the trained muscle, pre-workout) for the targeted anabolic hit — see the IGF-1 DES section of Somatropin, IGF-1 DES, PEG-MGF — the exogenous GH / IGF reference for the full mechanism and the honest note that IGF-1 DES has no human trials. This is a practitioner-community position, not a wellness-tier default; most readers get everything they need from the secretagogue protocol on its pre-bed schedule with the three signals dialed.

Why "more GH ≠ more IGF-1" — the case observation

The reader-question that titles this article: 186 baseline IGF-1 → 2.4 IU HGH/day for a period → labs back at 265 → dose raised to 4 IU HGH/day → next labs came back at 250, lower than the 2.4 IU number. Same user, more GH, less IGF-1 output.

The read: at least one of the three gating signals was under-dialed. The user’s caloric intake probably didn’t scale with the dose increase, or E2 drifted out of range, or training intensity plateaued. The extra GH had no unclaimed conversion capacity to use. Raising the dose again would produce the same result — or worse, because the higher GH exposure would recruit more side effects (water retention, joint feel, glucose dysregulation) without any additional IGF-1 payoff.

The wiki-level rule: if IGF-1 labs aren’t tracking upward with the peptide protocol, the dose is not the first lever to reach for. The three signals are. If a user has verified they’re eating enough, E2 is in range, and training intensity is real — then a dose increase is a reasonable next step. Without those three, dose is chasing a bottleneck that isn’t upstream.

The physiologic-restoration case for secretagogues

This is where the “GH → IGF-1 conversion is gated by three user-controlled signals” fact matters commercially: the same three signals gate IGF-1 output no matter where the GH came from. Whether the GH came from an injection of recombinant HGH (see Somatropin, IGF-1 DES, PEG-MGF — the exogenous GH / IGF reference on Somatropin) or from a secretagogue-driven pituitary pulse (see CJC-1295 / Ipamorelin), the liver runs the same conversion, and the same three signals decide what comes out the other side.

That means the honest secretagogue argument isn’t “these peptides are stronger than HGH.” They aren’t. It’s:

• If a user dials the three signals first, the physiologic pulses driven by the secretagogue path produce the same IGF-1 endpoint the user would get from exogenous HGH.
• The secretagogue path preserves the pituitary’s pulsatile rhythm and the somatostatin feedback brake (see Somatropin, IGF-1 DES, PEG-MGF — the exogenous GH / IGF reference for the pulse-vs-flood contrast).
• No prescription required. Lighter side-effect surface. Not the acromegaly-adjacent chronic-supraphysiologic-GH concerns of long-term HGH.
• For most wellness-tier goals — recovery, body composition, joint feel, sleep quality — the secretagogue path delivers what the reader is actually chasing.

Where the exogenous-HGH path is genuinely the right tool: clinically diagnosed adult GH deficiency (a prescription indication), or advanced-user protocols run through a supervising clinician. Not most readers. Somatropin, IGF-1 DES, PEG-MGF — the exogenous GH / IGF reference covers that path honestly.

Side effects of raising the GH signal (and how to titrate)

Any time the GH signal is genuinely elevated — from any source — a small cluster of side effects becomes more likely. They are cascade effects of increased GH, not of the specific peptide. They are managed the same way regardless of which secretagogue drove the pulse.

Water retention [ESTABLISHED]. GH influences renal handling of sodium and water. Increasing GH creates a temporary glitch in the kidney’s sodium/water management that takes 3–4 weeks for the body to normalize. During the acclimation window, the user may feel puffiness in the hands and face, joint pressure, and carpal-tunnel-adjacent sensations. This is not the peptide malfunctioning — it is the kidney learning to manage the new set point. Fix path:

• Lower the dose. If starting on Tesamorelin at 2 mg and hitting swelling / headaches, drop to 1 mg for 2–3 weeks, then titrate back up. If on CJC-1295 at 250 mcg, drop to 125 mcg, same titration window.
• Stay hydrated. Necessary but not sufficient — “just drink more water” alone is the wrong read; the problem is renal sodium management, not dehydration.
• Time it right. GH exposures in the morning tend to produce less noticeable water retention than pre-bed doses, because the circadian cortisol peak at wake-up acts as a natural diuretic and offsets the GH-driven retention. If a user’s pre-bed protocol is producing uncomfortable water retention, morning dosing is a reasonable practitioner-flexibility move — not the orthodox pre-bed protocol, but the mechanism supports it. Wait a short window before the first meal to preserve the fasted-GH lipolysis window.

Joint pressure and carpal-tunnel-adjacent sensations. Downstream of the water retention above and of direct GH/IGF-1 effects on soft tissue. Titration + acclimation resolves most cases. Persistent or severe symptoms are a signal the dose is too high — drop and re-titrate.

Thyroid interaction — GH accelerates peripheral T4 → T3 conversion [ESTABLISHED]. GH increases the rate at which T4 (the mostly-inactive precursor thyroid hormone) is converted to T3 (the active form) in the liver and kidneys. For most users, this is a feature — increased T3 amplifies the fat-loss signal in the intended direction. But for users on levothyroxine (synthetic T4) for Hashimoto’s or hypothyroidism, the accelerated conversion can produce a T4 shortage on the back end. The synthetic supply is being converted faster than the levothyroxine dose was calculated for. Fix path: check labs and be prepared to increase levothyroxine by ~25–50 mcg to compensate.

For users not already on thyroid medication, running a GH-axis protocol may unmask a subclinical T4 shortage that shows up on labs after starting. The correct order of operations is sleep + nutrition + protocol tuning first; add levothyroxine only if labs justify it, and only knowing that levothyroxine is suppressive to endogenous thyroid production and hard to come off — same class of dependency as chronic HGH.

Glucose / insulin resistance concerns. GH is counter-regulatory to insulin. At the pulse-pattern doses produced by wellness-tier secretagogue use, this is not a routine concern. At chronic supraphysiologic exposure (long-term HGH at body-composition doses), fasting glucose and HbA1c monitoring is the standard [ESTABLISHED — Somatropin, IGF-1 DES, PEG-MGF — the exogenous GH / IGF reference covers this].

Cancer-signaling caveat across the class. Elevated IGF-1 is the class-level oncology concern for anything that raises the GH-axis output. Practical rule: active malignancy or a personal history of cancer is a contraindication for elective GH-axis use. This is the honest read across the whole GH-axis category; the individual compound articles carry it in their own safety sections.

What this means for someone on Alyve secretagogue peptides

For a reader running CJC-1295 / Ipamorelin (the flagship 99.90% COA blend), Sermorelin, or Tesamorelin (99.46% COA):

1. Verify the three signals first. Enough calories to convert (protein target hit, not aggressively deficit); E2 in physiologic range (mid-range for most users, 40–60 pg/mL for men on gear); training intensity that actually produces adaptation demand. If any of these are under-dialed, dose changes are chasing the wrong lever.
2. Give the timing rhythm room to work. Pre-bed fasted dosing captures the natural GH pulse pattern — night-time lipolysis, morning-meal conversion to IGF-1 for tissue repair. This is the default for most wellness-tier goals.
3. Titrate side effects with dose, not with muscle-through. Water retention, joint pressure, and headaches on Tesamorelin at 2 mg or CJC at 250 mcg are signals to drop the dose for 2–3 weeks and let the body acclimate, then titrate up. This is faster than muscling through and produces a better protocol at steady state.
4. Check IGF-1 labs a few weeks in. IGF-1 is the mediator the reader is actually chasing. If the peptide protocol is producing an IGF-1 rise commensurate with the reader’s foundation quality, the protocol is working. If it isn’t, the answer is upstream in the three signals, not downstream in a dose increase.
5. The Hashimoto’s / levothyroxine note. Any reader on levothyroxine starting a GH-axis protocol should plan on a lab check + likely levothyroxine dose adjustment (~25–50 mcg upward) to keep T4 supply matched to the accelerated conversion.

The Alyve product

The GH-secretagogue lane is where the OHM catalog goes deepest — every peptide that drives the pituitary pulse the liver then converts to IGF-1 is stocked and third-party COA-verified:

• CJC-1295 / Ipamorelin — the flagship dual-receptor blend (99.90% COA, lot CJI583) — 5 mg / 5 mg, the most-used single-vial approach to running this pathway.
• CJC-1295 and Ipamorelin — the components sold separately if the reader wants finer control over ratios.
• Sermorelin and Tesamorelin (99.46% COA) — GHRH-analog alternatives with different profiles (Tesamorelin carries the strongest FDA-approved dossier of the group, Egrifta for visceral fat).

The supply-chain trust angle applies with force to this class specifically. Rough estimates put gray-market peptide contamination at ~25% fake or underdosed, and TFA-salt contamination is invisible to standard HPLC. For the GH-axis category — where the whole point is a real physiologic pulse driving a real liver conversion — verified purity is the floor, not a nice-to-have. Alyve’s US-manufactured stock with third-party Freedom Diagnostics COAs and >99% purity across the board is the verified-clean path to this pathway.

Offer: Use coupon OHM-15 for 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 attributes the sale to me — said plainly.) A 3-vial block on the CJC-1295 / Ipamorelin blend is the deepest-discount protocol run for this pathway.

Sources

1. — Josh Holyfield weekly-Q&A digest 2026-07-05. Central video: “More GH Doesn’t Mean More IGF-1 — Here’s Why.” Multi-topic Q&A; this article’s spine comes from Q&A blocks 2, 3, 4, 5, and 10 of that digest (HGH → IGF-1 conversion mechanism, three-signals-gate thesis, timing paradox, water-retention titration, HGH + Hashimoto’s T4 → T3 conversion). 6th Holyfield digest in the KB.
2. — companion Holyfield content on the CJC-1295 / Ipamorelin mechanism and expected timeline.
3. — companion Holyfield thyroid content (Reta-mediated TSH suppression, different mechanism than the GH-driven T4→T3 conversion covered here).
4. wiki/gh-igf-reference-cluster.md — the reference article for the compounds that drive this pathway (Somatropin, IGF-1 DES, PEG-MGF). This article covers the conversion; that article covers the compounds. Two halves of the same story.
5. wiki/cjc-1295-ipamorelin.md, wiki/cjc-1295.md, wiki/ipamorelin.md, wiki/sermorelin.md, wiki/tesamorelin.md — the upstream secretagogue peptides that feed this pathway.
6. wiki/igf-1-lr3-mgf.md — the honest-broker reference on the downstream IGF-analog family (IGF-1 LR3 and MGF direct-injected); cross-linked for the “why not just inject IGF-1” question.

• Insulin-dependency of hepatic IGF-1 production (Ho / Yakar / LeRoith line of work) — pin the specific primary reference for the “eating triggers the liver conversion” step.
• Estrogen (E2) modulation of GH-axis / hepatic IGF-1 production — pin the mechanism paper for the crashed-E2 → crashed-IGF-1-response clinical observation.
• Resistance-training-intensity → IGF-1 upregulation primary literature — pin the training-adaptation-and-IGF-1 mechanism.
• GH acceleration of peripheral T4 → T3 conversion + levothyroxine dose implications — pin the hepatic-deiodinase-modulation paper + the clinical observation on the 25–50 mcg levothyroxine adjustment.

See also: Somatropin, IGF-1 DES, PEG-MGF — the exogenous GH / IGF reference, CJC-1295, Ipamorelin, CJC-1295 / Ipamorelin, Sermorelin, Tesamorelin, IGF-1 LR3 and MGF — the IGF-1 axis muscle cluster, MK-677 (Ibutamoren), GHRP-2, GHRP-6, and Hexarelin — the injectable ghrelin-receptor GH peptides.